PDCD1 and colorectal carcinoma: In MSI CRC patients treated with anti-PD-1 ICB (KEYNOTE-177 clinical trial), durable responders had significantly higher probability to be called as ISC1a than PR/non-responders (Fig. 7a), whereas for the latter patients the pattern was completely opposite (Fig. 7b).